Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Johnson & Johnson Pharamceutical Research & Development, L.L.C
Woman and Man Max 99 years
Johnson & Johnson Pharamceutical Research & Development, L.L.C
Update Il y a 4 ans
Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the safety profile of CG5503 base IR 50 mg or 100 mg taken every 4 to 6 hours as needed over the long term exposure of 90 days
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Johnson & Johnson Pharamceutical Research & Development, L.L.C
Update Il y a 4 ans
A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease
The primary objective of this study is to determine the efficacy of CG5503 immediate-release (IR) using the sum of pain intensity difference (SPID) over 5 days compared with placebo, and to assess the...
Country
None
organs
None
Specialty
None
unknown
More information